Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPSCVY)

• Drug Name: CMX-2043 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Cardiac disease	BA00-BE2Z	Phase 2	[1]
Myocardial reperfusion injury	NB31	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 49802864
  CAS Number: CAS 910627-26-8
  TTD Drug ID: DMPSCVY

Molecule-Related Drug Atlas

Drug(s) Targeting Proto-oncogene c-Met (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[4]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[5]
Amivantamab	DMZ7AMY	Non-small-cell lung cancer	2C25	Approved	[6]
Capmatinib	DMYCXKL	Non-small-cell lung cancer	2C25.Y	Approved	[7]
Tepotinib	DMUQ0E8	Non-small-cell lung cancer	2C25	Approved	[8]
RG3638	DMTQJE0	Gastric adenocarcinoma	2B72	Phase 3	[9]
Savolitinib	DMALFKX	Renal cell carcinoma	2C90	Phase 3	[10]
Beperminogene perplasmid	DM6RWBN	Critical limb ischemia	BD4Y	Phase 3	[11]
Tivantinib	DMNVP8Q	Hepatocellular carcinoma	2C12.02	Phase 3	[12]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[9]

Drug(s) Targeting RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[10]
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[10]
GDC-0068	DMWBZJD	Breast cancer	2C60-2C65	Phase 3	[10]
CI-1033	DMSI8N3	Lymphoma	2A80-2A86	Phase 2	[13]
ARQ 092	DM5WK0J	Proteus syndrome	LD2C	Phase 2	[14]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[15]
RX-0201	DMTBAV3	Pancreatic cancer	2C10	Phase 2	[16]
PTX-200	DM0ZIT2	Breast cancer	2C60-2C65	Phase 2	[10]
Triciribine prodrug	DMBN1XS	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[15]
M2698	DM3PVBJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Modulator	[1]
RAC-alpha serine/threonine-protein kinase (AKT1)	TTWTSCV	AKT1_HUMAN	Modulator	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02103959) Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography. U.S. National Institutes of Health.
• [3] Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Clinical pipeline report, company report or official report of Exelixis (2011).
• [6] Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
• [13] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
• [16] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.